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Key Points:


In the perioperative surgical home model, anesthesiologists are well positioned to manage
complex patients, including those who are opioid-tolerant, due to their training and
expertise in pharmacology.



Opioid-tolerant patients present challenges for postoperative analgesia, posing dual risks
of poor pain control and medication-related toxicity.



Reduction of opioids through regional anesthesia techniques and multimodal non-opioid
agents can improve analgesia and minimize opioid-related complications in the high-risk
opioid-tolerant population.

Synopsis:
Management of acute postoperative pain is important to decrease perioperative morbidity
and improve patient satisfaction with the healthcare experience. Although they are indispensable
agents in most surgical settings, opioids are associated with potential adverse events that may lead
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to significant risk. Uncontrolled pain is a risk factor in the transformation of acute pain to chronic
pain. Balancing these issues can be especially challenging in the opioid-tolerant patient undergoing
surgery, for whom rapidly escalating opioid doses in an effort to control pain can be associated
with increased complications. In the perioperative surgical home model, anesthesiologists are
positioned to coordinate a comprehensive perioperative analgesic plan that begins with the
preoperative assessment and continues through discharge. Multimodal analgesia may improve
pain control while reducing opioid-related complications, and should include regional techniques
when possible and adjunct agents throughout the perioperative period to reduce opioid
requirements. With patient safety as a guiding principal, a physician-led acute pain service can
coordinate the appropriate approaches to postoperative monitoring and the management of
peripheral nerve catheters, parenteral drug delivery techniques, and conversion to oral opioid
regimens.
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Introduction
Acute pain is a major concern of many patients preparing to undergo surgery. The
incidence of postoperative acute pain varies widely in the literature. It has been reported as high
as 80% and is likely underreported (1). Such data suggest that uncontrolled acute postoperative
pain continues to be an unmet need and a target for improvement. This is further compounded in
the opioid-tolerant patient receiving chronic opioids at baseline. While preparing to manage the
opioid-tolerant patient, mechanisms underlying chronic postsurgical pain, acute opioid tolerance,
and opioid-induced hyperalgesia are poorly understood but highly relevant. The emerging model
of the perioperative surgical home puts anesthesiologists in position to best address complicated
patients, particularly those with pre-existing chronic pain conditions and who are opioid-tolerant
as a result of chronic opioid therapy.

The Perioperative Surgical Home
The perioperative surgical home (PSH) has been supported by the American Society of
Anesthesiologists (ASA) to improve outcomes while improving efficiency, broadening the role of
the anesthesiologist in preoperative, intraoperative, and postoperative care. It is defined by the
ASA as “a patient-centered and physician-led multidisciplinary and team-based system of
coordinated care that guides the patient throughout the entire surgical experience” (2). The “Triple
Aim” goals of the PSH as described by Berwick et al (3) include: 1) improving the individual
experience of care, 2) improving the health of populations, and 3) reducing the per capita cost of
care.
The PSH for surgical patients has been compared to the Patient-Centered Medical Home
(PCMH) for primary care. Recent data suggest that the PCMH improves outcomes and reduces
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costs (4). Development of the PSH requires the support of hospital administration and
collaboration of surgeons and anesthesiologists. Anesthesiologists are particularly well suited to
staff the PSH (4) as the physician team leader. Since many institutions do not have an existing
preoperative anesthesia clinic, development of a PSH can be financially challenging. If there is
institutional support or desire for PSH development, the institution and anesthesia practice need to
be financially “aligned” with an agreement to support funding (4). Compensation for staffing also
needs to be considered. Hospital administration may be willing to compensate anesthesiologists
for this practice if a financial benefit can be demonstrated. Reimbursement for anesthesiologists
may mirror that of internists in the PCMH, as the Centers for Medicare and Medicaid Services
have recognized the value of the PCMH (Kain). Future payment models that include bundled
payments for services may make anesthesiologist compensation complicated.
Once the PSH is implemented, services begin with early patient engagement after the
decision for surgery is made. The surgical experience is treated as a fluid continuum rather than
discrete pre-, intra-, and post-surgical phases. It involves appropriate risk stratification and
preoperative testing, decreased redundancy in testing, improved operating room efficiency,
decreased variability through the use of evidence-based surgical care pathways, and postsurgical
care initiatives (5). We will focus on management of the opioid-tolerant patient within the PSH.

Opioids
Opioids remain a mainstay of analgesia regimens for the surgical patient. Prescriptions for
opioids, as well as the increased incidence of prescription opioid abuse have been on the rise in
recent years, especially in the United States and Canada. Opioid-related deaths and adverse events
have seen a similar spike (6). Yet, despite the increased use of opioid medications to manage pain
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and improve function, there remains a serious and significant mismatch between the number of
prescriptions issued and positive end-outcomes of pain care in the United States (7). In some
patients, chronic opioid exposure, especially at high doses, has been attributed to to a progressive
reduction in analgesia while increasing risks of opioid tolerance, opioid-induced hyperalgesia, and
medication misuse (8). These issues come into focus when patients on chronic opioid therapy
have indications for surgery.

Opioid Tolerance


A phenomenon whereby increasing opioid doses are required for analgesia due to a
desensitization of pain signaling at the opioid receptor (9).



Acute opioid tolerance (AOT) may develop rapidly in patients who are opioid-naïve (10).



Patients exposed to high intraoperative opioid doses have demonstrated increased
postoperative pain and opioid requirements.



These higher opioid doses are associated with an increased risk of adverse events (9).

Opioid-Induced Hyperalgesia (OIH)


Nociceptive sensitization likely caused by neuroplastic changes in the central and
peripheral nervous systems caused by opioid exposure, leading to paradoxical worsening
of pain with increasing opioid doses.



Remifentanil has been particularly implicated, but it may occur with acute or chronic
exposure, high or low doses, and any opioid or route of administration (11).



Prevalence of OIH is likely underappreciated as its diagnosis can be very challenging and
it can be confused with tolerance, worsening disease, or even opioid withdrawal.

7


When OIH is suspected, opioid dose reduction may improve analgesia. Other proposed
treatments include opioid rotation, N-methyl-D-aspartate (NMDA) receptor antagonists
(ketamine, memantine, dextromethorphan), interventional pain management, or behavioral
management (11).



Rotation to methadone is of particular interest since it is both a mu-receptor opioid agonist
and an NMDA-receptor antagonist.

Managing acute postoperative pain may be especially challenging in the opioid-tolerant
patient, and increasing doses of opioids to overcome tolerance is a poor management strategy as
this may result in unwanted opioid side effects, including sedation, respiratory depression, ileus,
and paradoxical worsening of pain. Multimodal analgesia involves the incorporation of several
medications with unique mechanisms of action in an effort to improve analgesia and minimize the
side effects of any one class of medication, especially opioids. These patients may benefit the most
from preoperative optimization of their pain regimen, context-appropriate selection of
intraoperative anesthetic techniques, and a multimodal postoperative analgesic plan.

Preoperative Assessment
In the PSH, the preoperative assessment begins in the preoperative clinic rather than at the
bedside on the day of surgery. Patients often encounter their anesthesiologist for the first time in
the pre-surgery “holding area” minutes before surgery, whereas a previously scheduled
comprehensive assessment in the clinic affords time to enact a management plan for the opioidtolerant patient. This anticipatory planning and care coordination also creates the opportunity to
provide perioperative education, to set expectations, and alleviate patient anxiety. Managing
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patient expectations for pain management is critical to success, and enhances patient satisfaction.
Both surgeon and anesthesiologist should be attuned to early identification and management of the
opioid-tolerant patient.
Assessment begins with a thorough history and physical examination and includes
elucidation of the location and nature of chronic pain, as well the degree of functional impairment.
Particular attention should be paid to the patient’s current pain regimen, including exact doses,
schedule, route(s) of administration, prescriber, and effects (positive and negative). A complete
history includes past medication use and experiences (Table 1). Patients who cannot provide
evidence of accountability for their opioids justify additional exploration into opioid abuse, misuse
or diversion. A urine drug screen may be useful to determine potential substance misuse, abuse or
diversion. In the face of active, undiagnosed substance abuse, a joint decision between the surgeon
and anesthesiologist should be made, weighing the risks of the abuse on both the patient’s current
health and surgical outcome. A more detailed discussion of substance abuse is out of the scope of
this article.
The nature of the proposed surgery is important in determining the anesthetic and analgesic
plan. Is it major surgery requiring hospital admission with high levels of anticipated pain? On the
other hand, is discharge home on the same day anticipated? Is the procedure and medical
circumstances of the patient suitable for a regional anesthetic technique? Would any drugs or
techniques be contraindicated because of patient characteristics (e.g. renal or liver disease) or
surgical type (e.g. positioning, bleeding risk or bone healing)?
Taking into account the patient’s medical history, planned surgery, current therapies, and
existing and anticipated pain, the anesthesiologist may tailor a specific anesthetic plan that
involves a combination of pre-emptive analgesia, regional techniques, intraoperative agents, and
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postoperative multimodal analgesia. Multimodal regimens are especially important for the opioidtolerant patient, with the goals of adequate analgesia, prevention of chronic post-surgical pain
(CPSP), and minimization of opioids and their associated adverse events. Chronic exposure to
opioids reduces drug efficacy, requiring increasing doses to achieve similar analgesic effects.
These patients may be at increased risk when compared to opioid-naïve patients, where increasing
dosages to improve efficacy increases risk of adverse events, most significantly respiratory
depression. Additionally, opioid-tolerant patients presenting for surgery may have altered pain
sensitivity that includes generalized hyperalgesia or ill-defined pain remote to the surgical site
(12). We are therefore left to maximize the utility of non-opioid agents and regional techniques.
The advantages of a patient-specific analgesic plan are several-fold: first, the patient will
be well informed about expectations and will not be expected to make decisions about his or her
care immediately prior to or after surgery when they are likely to be in a more anxious, distressed,
or cognitively impaired state from sedatives or anesthetics. From an ethical standpoint, this is
important with regard to adequacy of informed consent. Second, communication is improved with
the intraoperative anesthesia team when there is sufficient time for concerns of all parties to be
elicited, discussed and clarified. Finally, this early encounter and assessment affords time to
prepare for and enact management plans for specific therapies.
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Table 1: Components of the preoperative assessment for the opioid-tolerant patient.
The Preoperative Assessment


Clarification of pre-existing pain and functional limitations



Current opioid medications, including dose, frequency, and any changes in dose in the
past six months



Current opioid prescriber and dispensing pharmacy



Current non-opioid analgesics (e.g. acetaminophen, NSAIDs, COX-2 inhibitors,
antineuropathic agents, benzodiazepines, muscle relaxants)



Past opioid medications and their effectiveness and tolerability of side effect profile



Review of potential misuse or abuse of opioids



Discussion of expectations and anticipated level of pain associated with the particular
procedure (mild, moderate, severe) including perceptions from past surgical experiences
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Opioid Agonists
The anesthesiologist must first determine which patients require extra attention and should
be considered “opioid-tolerant.” Tolerance is defined by the FDA as the use of greater than or
equal to 60 mg of oral morphine equivalents per day for 7 days or longer, regardless of long-term
opioid use (5). Opioid-tolerant patients may be taking a variety of opioids at home in immediaterelease, short-acting (e.g. oxycodone, hydrocodone, morphine, oral transmucosal fentanyl) or
extended-release, long-acting (e.g. MSContin, OxyContin, transdermal fentanyl patch)
preparations. Routes of administration may include oral, subcutaneous, transdermal, or intrathecal
delivery. Patients should be advised to continue their usual analgesic regimen, including regularly
scheduled immediate- or extended-release and transdermal agents.
Methadone is a mu-receptor opioid agonist that may be prescribed for the treatment of
chronic pain or as a once-daily opioid replacement therapy for addiction. These patients have
tolerance to opioids, but may also have increased pain sensitivity (13). Patients on methadone for
both chronic pain or methadone maintenance therapy (MMT) should continue their scheduled
regimen perioperatively to avoid fluctuations in methadone levels given its long half-life (13, 14).
An evidence-based multimodal analgesic plan is necessary for opioid-tolerant patients to
provide adequate analgesia and prevent withdrawal but also to reduce the length of hospital stay
and prevent occurrences of readmission (5). Despite the FDA definition of tolerance, in clinical
acute pain practice, chronic use of relatively low levels of daily opioid exposure (20 mg morphine
equivalents daily for greater than 7-10 days) can significantly reduce the effectiveness of
postoperative opioids, leading to poorly controlled pain.
The specific components of any multimodal analgesic plan will vary based on specific
patient and surgical factors, but includes regional or neuraxial anesthesia/analgesia when possible,
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non-opioid adjunct agents (e.g. NSAIDs/COX-2 inhibitors, acetaminophen, gabapentinoids,
alpha-agonists, intravenous lidocaine), and NMDA-receptor antagonists (e.g. ketamine), using
opioids for rescue analgesia only. Preoperative dosing of non-opioid analgesics is gaining
popularity and typically involves medications taken prior to surgery and continued around-theclock postoperatively (Table 2). Pregabalin (15, 16, 17, 18), gabapentin, and celecoxib (19) have
demonstrated benefit when started preoperatively in reducing the need for postoperative opioids.
The combination of acetaminophen, pregabalin, and celecoxib has shown benefit when started
preoperatively and continued around-the-clock postoperatively (20). At the authors’ institution,
this has been adopted for orthopedic, urologic, and gynecologic procedures.
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Table 2. Multimodal Non-opioid Agents for Preemptive Analgesia
Drug
Acetaminophen
Celecoxib
Pregabalin
Gabapentin

Administration
Route
PO
PO
PO
PO

Suggested Dose (Two hours before surgery)
1000 mg (over 50 kg)
200-400 mg
75-150 mg
900-1200 mg
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Intraoperative Management
In the PSH model, the anesthesiologist caring for the patient on the day of surgery will
have the advantage of the thorough preoperative assessment and management strategy already in
place. The anesthesiologist can then advise the patient of the finalized anesthetic plan. Patients
should continue their analgesic regimen up until the time of surgery, including any morning doses
of opioid.
While tailoring the analgesic plan, the anesthesiologist must also take into account the
nature of a patient’s pain and the mechanisms of analgesic agents to be used. Pain is complex and
subjective and there are five generally recognized categories of pain: nociceptive, neuropathic,
psychogenic, mixed and idiopathic (21):


Nociceptive pain can be described as sharp or dull, aching, throbbing, pressure-like
or feelings of stiffness.



Neuropathic pain is often burning, shock-like tingling or stabbing.



Mixed pain is a result of stimulation of both nociceptive and neuropathic pathways.



Psychogenic pain is pain that is thought to be an emotional or psychiatric
phenomenon, only to be considered once all other nociceptive or neuropathic
etiologies have been ruled out.



Idiopathic pain is due to unknown origin.

The concept of multimodal analgesia takes into account understanding the type of pain in
need of treatment and targeting it at multiple sites along the pain pathway to achieve a synergistic
effect with different classes of analgesics.


Opioids act both supraspinally via inhibitory pathways as well as in the dorsal horn
to impede nociception.
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NSAIDs act both in the spinal cord and periphery, inhibiting cyclooxygenase to
decrease inflammation secondary to prostaglandins and further decrease
nociception.



Acetaminophen acts centrally likely via inhibition of cyclooxygenase in treating
nociceptive pain.



Local anesthetics act at central, spinal and peripheral sites, depending on route or
localization of administration.



NMDA receptor antagonists, exerting effects in the dorsal horn, inhibit nociceptive
and neuropathic pain.



Gabapentinoids bind to calcium channels in the spinal cord and brain to decrease
neuropathic pain.

Although opioid-tolerant patients presenting for surgery will need opioids perioperatively,
multimodal pain regimens are paramount in managing acute surgical pain in these cases. This may
include the use of intraoperative adjuncts such as epidural/ regional analgesia, ketamine,
dexmedetomidine, and lidocaine infusions.

Ketamine
A single dose of opioid will lead to activation of NMDA receptors (22). In theory, tolerance
and hyperalgesia begins with the first dose of an opioid. In animal studies, ketamine, an NMDAreceptor antagonist, reversed morphine tolerance and improved effectiveness while additionally
preventing acute tolerance. (23). The use of ketamine as an analgesic adjunct in opioid-naïve
patients resulted in decreased opioid requirements after surgery, fewer opioid-related side effects
such as nausea and vomiting, and possibly prevention of chronic pain and hyperalgesia (24, 25,
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26). Few studies, however, have examined the effect of intraoperative ketamine in opioid-tolerant
patients.
A study by Loftus et al (27) showed that intraoperative ketamine infusions resulted in
reduced opioid requirements in the first 48 hours and at 6 weeks postoperatively in opioiddependent patients undergoing back surgery. Additionally, average pain scores were significantly
reduced in the postanesthesia care unit and at 6 weeks postoperatively (27). The authors
recommended patients taking greater than or equal to 30 mg per day of morphine equivalents with
expected moderate-severe postsurgical pain receive a bolus of ketamine of 0.5 mg/kg followed by
infusion of 0.25 mg/kg/hr intraoperatively.
Postoperatively, ketamine infusions may be safely administered without continuous
cardiac or respiratory monitoring (ICU or telemetry) (28). An in-house APMS team is crucial to
provide regular monitoring of analgesia and titration. Although studies demonstrate that it is well
tolerated, patients should be monitored for neurological and psychological side effects.

Regional Anesthesia and Analgesia
A number of surgical procedures, including extremity surgery, carotid endarterectomy, and
hernia repair, may be done under a regional/neuraxial block as the sole anesthetic, thus decreasing
the reliance of opioids in an opioid-tolerant patient.
Although general anesthesia is often indicated, regional analgesia as part of a multimodal
regimen decreases opioid burden in these challenging patients. The use of long-acting local
anesthetics and continuous catheters enable regional analgesia to be effective during the first few
days following surgery when acute pain is most severe.
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Utilization of perineural catheters results in prolonged postoperative pain control
(including resting and dynamic pain), accelerated resumption of therapy, less reliance on opioids,
fewer sleep disturbances, and overall increased patient satisfaction (29). Epidural analgesia results
in improved rehabilitation, better pain control, and decreased opioid consumption when compared
to opioids alone (30).
Appropriate regional techniques, including single-shot or continuous peripheral nerve
blocks, or epidural analgesia, should be employed whenever possible. Although regional
anesthesia offers many benefits in opioid-tolerant patients, opioids must judiciously be continued
to prevent withdrawal and to treat the chronic pain not related to the surgical procedure.

Lidocaine Infusions
The use of an intravenous lidocaine infusion has been widely studied in abdominal surgery.
In open and laparoscopic abdominal surgery, an intravenous lidocaine infusion resulted in
decreased postoperative pain for 48 hours postoperatively, reduced opioid consumption, earlier
return of bowel function, earlier rehabilitation and decreased length of stay (31).
When compared to thoracic epidural analgesia in patients undergoing colorectal surgery,
intraoperative and postoperative lidocaine infusions resulted in similar times to return of bowel
function and time to discharge; however, epidural analgesia resulted in lower numeric pain scores
(32).
The benefit of intraoperative lidocaine infusions may not apply to all types of surgery as
the addition of lidocaine in patients undergoing mastectomy did not result in decreased pain or
reduced opioid consumption when compared to placebo (33). Although the use of intraoperative
lidocaine infusions has not been well studied in the opioid-tolerant population, current literature
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suggests it may be useful as part of a multimodal regimen when regional techniques are
contraindicated. A common dosing strategy is 1.5 mg/kg loading dose followed by 1.5 mg/kg/hr
intraoperatively.

Dexmedetomidine
With high density of receptors in the dorsal horn, alpha-2 adrenergic agonists act on the
central nervous system to reduce pain. Dexmedetomidine is a highly selective alpha-2 agonist that
acts as a sedative, anxiolytic, sympatholytic, and analgesic with minimal respiratory depression.
In rats with presumed neuropathic pain, dexmedetomidine exhibited anti-hyperalgesic
action (34). In patients undergoing laparoscopic bariatric surgery, randomized to receive 0.2, 0.4
or 0.8 mcg/kg/h dexmedetomidine infusion intraoperatively, dexmedetomidine decreased opioid
use, need for antiemetic treatment, and length of stay in the PACU, but did not change opioid use
patterns or quality of recovery beyond the PACU (35).
Given the cardiovascular effects of dexmedetomidine infusions, namely bradycardia and
hypotension, Tufanogullari et al (35) recommended 0.2 mcg/kg/h infusion intraoperatively as an
analgesic adjunct. Gurbet et al (36) showed an intraoperative dexmedetomidine rate of 0.5
mcg/kg/hr decreased 48-hour opioid consumption with no change in pain scores following total
abdominal hysterectomy when compared to placebo. Although dexmedetomidine has not been
specifically studied in the opioid-tolerant population, the literature suggests a continuous infusion
during surgery may decrease intraoperative opioid requirements. It is likely that continuation of
dexmedetomidine is necessary to extend opioid reduction beyond the PACU.

Postoperative Management
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The care of the opioid-tolerant patients continues well beyond the operating room and into
the post-anesthesia care unit (PACU) as part of the PSH model. Although the surgeon typically
orders analgesics for the patients when on the medical ward, there is substantial opportunity for
input and collaboration by the anesthesiologist. Medication management and expectations for
postoperative analgesia can be established early on and can help create a positive patient
experience.
In this section, strategies to managing postoperative analgesia for the opioid-tolerant
patient will be discussed, including:


Benefits of a non-opioid multimodal approach



Resuming home medications, including opioid agonist-antagonists



The role of acute pain services in the perioperative surgical home model

Multimodal Approach to Postoperative Analgesia
Inadequate postoperative pain management has been linked with complications, including
myocardial ischemia, impaired pulmonary function, ileus, thromboembolism, impaired immune
function, wound infection and anxiety (37). Additionally, hospital reimbursements are now linked
to patient satisfaction scores (HCAHPS). Pain is a significant driver of poor patient satisfaction.
Poor outcomes related to uncontrolled pain result in greater healthcare costs.
Multimodal analgesia has been successfully implemented into multiple surgical pathways,
and has been shown to reduce opioid consumption (38), surgical complications (38, 39), and length
of hospital stay (38, 39, 40). Some agents that have been used successfully in multimodal pathways
include acetaminophen (PO and IV), cyclooxygenase-2 (COX-2) inhibitors, gabapentinoids
(gabapentin and pregabalin), non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids,
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local anesthetics, α-2 agonists (clonidine and dexmedetomidine), and ketamine (Table 3). To the
extent possible, these agents can be used to minimize opioids and improve analgesia.
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Table 3. Multimodal Non-Opioid Agents for Postoperative Analgesia
Drug
Acetaminophen
Ibuprofen
Ketorolac
Celecoxib
Gabapentin
Pregabalin
Ketamine

Administration
Route
PO/IV
PO
PO/IV
PO
PO
PO
IV

Suggested Dose and Frequency
1000 mg q6h (over 50 kg)
600 mg q6h
15 – 30 mg q6h
200 – 400 mg q12h
600 – 800 mg TID
75-150 mg q12h
0.5 mg/kg bolus; infusion 0.25 mg/kg/hr
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Multimodal analgesia pathways have existed for more than 15 years but Kehlet and
colleagues (41) were the first to describe pathways leading to clinically important outcomes, such
as reduction in length of hospital stay in colorectal procedures. There have been several large
reviews and meta-analyses summarizing the literature on several multimodal agents, with both
gabapentin (42) and pregabalin (43) demonstrating an opioid-reducing effect when used in a
multimodal pathway. The addition of a NSAID to an opioid as part of a multimodal pathway
provides better analgesia than the opioid alone (44). Taken together, these studies provide evidence
that using non-opioid agents whenever possible can improve analgesia, and this is even more so
for the opioid-tolerant patient.
Because the doses of opioids taken chronically by the opioid-tolerant population often
exceed many physicians’ comfort levels, surgeons frequently seek recommendations on discharge
regimens. Conversion from IV to oral opioids requires experience and expertise of a physician
experienced in pain management (45).

Postoperative Oral Analgesics and Restarting Home Medications
If

the

patient

was

taking

a

combination

opioid

preoperatively

(e.g.

hydrocodone/acetaminophen), that creates an opportunity for the anesthesiologist to initiate a
discussion with the surgeon about postoperative analgesics. Non-opioid adjuncts, such as
acetaminophen, NSAIDs, and gabapentinoids, should be initiated as the mainstay of treatment,
with opioids for breakthrough pain only. Unless the patient underwent gastrointestinal surgery or
cannot take anything by mouth for other reasons, oral medications may be started on the evening
of the day of surgery. However, for patients admitted to the hospital after painful surgery,
intravenous opioids are often needed. Opioids delivered via IV patient-controlled analgesia (PCA)
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lead to better patient satisfaction than intermittent boluses given via oral, IM, or IV routes, as well
as lower rates of adverse events (46). More potent opioids, such as hydromorphone or sufentanil,
may be considered when treating opioid-tolerant patients. Higher-dose PCA settings may be
needed to deliver adequate analgesia.

Special Considerations: Opioid Addiction Therapy
Patients treated for opioid addiction present a particular challenge in that many have a
history of longstanding opioid abuse with significant tolerance and hyperalgesia. It is not unusual
for patients in recovery to be exceedingly fearful of exposure to non-maintenance opioids if they
are on such a regimen, or re-exposure to opioids if they have managed to be fully abstinent. In
addition to the opioid agonist methadone, patients being treated with opioid-replacement therapy
(ORT) may be maintained on buprenorphine (categorized as a partial agonist, although its
pharmacology is debated) or an opioid antagonist (naltrexone), each with unique considerations.

Buprenorphine
Buprenorphine is a semisynthetic opioid with a high mu-receptor binding affinity. It is
marketed as a sole agent (Subutex) or in combination with naloxone (Suboxone) to deter abuse. A
transbuccal patch delivery form of buprenorphine has been recently approved by the FDA for the
treatment of chronic pain, There are limited data to guide perioperative management of patients
taking buprenorphine; furthermore, its high binding affinity, slow dissociation, and analgesic
“ceiling effect” may make adequate analgesia a challenge.
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Analgesic strategies for patients on buprenorphine mainly stem from expert opinion and
case reports. Bryson (13) describes two basic treatment options as continuing buprenorphine
throughout the perioperative period or stopping buprenorphine prior to surgery.
There is no clear consensus on the best strategy for managing buprenorphine
preoperatively, with many recommending it be stopped preoperatively to avoid the analgesic
ceiling effect of buprenorphine or the high dose of supplemental opioids that may be required.
Discontinuation of ORT, however, carries a risk of relapse that will need to be evaluated on an
individual patient basis. Considering the high prevalence of substance abuse and addiction in the
United States, involving consultants with addiction medicine expertise on perioperative teams may
be a useful approach going forward.
In patients for whom the medication is discontinued preoperatively, it should be stopped
three days prior to surgery. As long as the drug has been given sufficient time to be metabolized
by the liver and excreted by the biliary system (typically 72 hours), mu-opioid agonists may be
effectively used for postoperative analgesia, taking into account that most of these patients are
opioid-tolerant and require larger than standard doses. Although the duration of action for
buprenorphine is about 40 hours (47), the elimination half-life after a sublingual dose is 37 h (48).
If buprenorphine-naloxone was given within the preceding three days before surgery, its effects
may still be present as it has a very strong binding affinity for the μ-opioid receptor and
dissociates very slowly from the receptor (47). If opioids are used for postoperative analgesia, the
resulting analgesia may not be adequate using routine clinical doses if some of the buprenorphine
is still present due to competitive binding of burprenorphine and its “ceiling” effect. Emphasis
should be on regional anesthesia techniques and non-opioid agents, especially ketamine as a potent
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analgesic that does not affect respiratory drive (49) and provides the most benefit after painful
procedures (50).
For patients who continue taking buprenorphine-naloxone through the perioperative
period, buprenorphine can provide sufficient and potent opioid analgesia as a partial mu-opioid
agonist, and for minor procedures may be adequate without much supplementation (13). For major
surgery, however, additional analgesics will likely be needed. One author recommends the use of
short-acting opioids, such as fentanyl, if a once-daily dosing regimen of buprenorphine-naloxone
is continued perioperatively (13), though he noted that “much higher” doses might be required.
Additional doses of buprenorphine are often sufficient to manage pain within a multimodal
analgesic regimen. Trying to “overpower” the effect of buprenorphine with other opioids may
provide unpredictable results as well as unpredictable opioid side effects. For upper- or lowerextremity surgery, peripheral nerve blocks can often eliminate the need for supplemental opioids.
A multimodal strategy will help minimize opioids. Early involvement by an acute pain
management service is recommended.
In the absence of definitive recommendations, the anesthesiologist will help decide
whether to discontinue or continue the buprenorphine preoperatively, possibly in conjunction with
the prescribing physician who should be involved with post discharge planning and management.
It cannot be emphasized enough how important collaboration and coordination are for safe and
effective perioperative care of this complicated patient population.

Naltrexone
In contrast to buprenorphine or methadone, naltrexone is a full opioid competitive
antagonist used in the treatment of opioid and alcohol addiction, and is available as a once-daily
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oral agent or a monthly depot injection (Vivitrol). Overcoming the competitive blockade with
opioid agonists to achieve analgesia requires markedly high doses of opioid medications and is not
recommended. With the plasma half-life of oral naltrexone at 4 h, and that of the active metabolite
at 13 h, patients should be advised not to take their once-daily dose on the morning of surgery (13).
With the monthly depot injection, the antagonism lasts roughly 30 days, and elective surgery
should be delayed until at least 30 days after the last naltrexone injection if possible (13).
Patients treated for opioid addiction benefit from a preoperative plan regarding
management of antagonist/mixed agents but may present for surgery, either emergently or having
bypassed preoperative assessment, without such a plan. A careful discussion among the patient,
the anesthesiologist, and the surgical team is important, as opioids will be less effective or even
ineffective in the setting of these agents. A decision will need to be made to proceed, maximizing
non-opioid medications in a multimodal strategy, or to delay surgery.

To summarize the recommendations for managing postoperative analgesia for patients
taking buprenorphine-naloxone through the perioperative period undergoing moderately or
severely painful surgery:


Incorporate regional anesthesia techniques whenever possible



Administer non-opioid adjuncts unless contraindicated



If opioids are utilized, higher doses may be needed, the analgesic effect may be
less, and the resulting side effects greater, justifying appropriately increased levels
of monitoring



Consider involving an acute pain management service early
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Acute Pain Management Services in the Perioperative Surgical Home
The postoperative period presents an excellent opportunity for an anesthesiologist-led
acute pain management service (APMS) to actively help guide the patient through hospitalization
until discharge and beyond. Delivering the patient safely through the intraoperative period is no
longer sufficient. Adequate postoperative analgesia is a key area within the PSH that has an impact
on long-term outcomes for the patient. In the case of opioid-tolerant patients, the postoperative
period is frequently the most challenging. Careful planning may yield significant improvements
for these patients.
Continuous peripheral nerve blocks have continued to increase in popularity, especially in
opioid-tolerant patients (51). The APMS has an important role in managing continuous peripheral
nerve blocks and providing patient education. At the authors’ institution, the APMS physicians
and colleagues skilled in regional anesthesia techniques work together to manage these patients
who received a peripheral nerve block, including providing 24-hour coverage via a beeper that
patients may call for problems or questions. Regional anesthesia and analgesic techniques will
likely become even more important as their inclusion in surgical pathways increases (45).
To summarize the benefits of an APMS in the perioperative surgical home in the setting
of opioid-tolerant patients in the postoperative period:


Management of continuous peripheral nerve blocks, including titration, side effects,
and ambulatory catheter instructions, from the recovery room until discharge and
beyond



Initiation and management of adjunctive medications, such as ketamine, that
require expertise beyond the typical analgesic regimen
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Guidance and recommendations on opioid conversions and discharge regimens that
include high opioid doses

Conclusion
Management of acute pain with minimization of adverse events in the opioid-tolerant
patient undergoing surgery can be extremely challenging. The anesthesiologist, using his or her
expertise in regional anesthesia techniques and pharmacology, can improve patient care within the
PSH by implementing a comprehensive opioid-reducing strategy for opioid-tolerant patients that
begins in the early preoperative period. Intraoperative care of these patients relies heavily on a
multimodal analgesic regimen to minimize required opioids, and a postoperative APMS may help
transition from the hospital setting to discharge. Anesthesiologists are expected to be involved in
the entire perioperative process. Challenging patients, such as the opioid-tolerant, demand our
expertise, especially as the specialty of anesthesiology evolves to perioperative medicine.
For those practitioners working in institutions without discrete acute pain services or
perioperative surgical home, a good place to start is to initiate discussions with the Quality
Assessment and Performance Improvement team to bring these issues to the forefront. Interested
practitioners can also approach their anesthesia and surgical colleagues to spark initiatives.
Collaboration with anesthesia departments at other institutions who have implemented some
elements of the PSH can be extremely helpful, especially with administrative or financial concerns.
Changing institutional culture is difficult and individual champions for improvement can be
confronted by resentment if they take these issues on alone.
Future study will be needed to demonstrate the efficacy of the PSH, but the benefits seen
by similar programs and the support of the ASA give optimism. The Triple Aim requires not only
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anesthesiologist expertise, but also collaboration with physician colleagues and hospital
administration. Through continued improvement measures, anesthesiologists are positioned to
greatly improve the perioperative continuum.
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